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Summary
Cardiovascular disease (CVD) and osteoporosis are common
age-related conditions associated with significant morbidity,
mortality, and disability. 
Traditionally, these two conditions were considered unrelated
and their coexistence was attributed to independent age-relat-
ed processes. However, an increasing body of biological and
epidemiological evidence has provided support for a link be-
tween the two conditions that cannot be explained by age
alone. Several hypotheses have been proposed to explain the
link between osteoporosis and CVD including: 1) shared risk
factors, 2) common pathophysiological mechanisms, 3) com-
mon genetic factors, or 4) a causal association. 
This review highlights the epidemiologic literature on the as-
sociation of bone density with cardiovascular mortality, car-
diovascular morbidity, and subclinical measures of athero-
sclerosis. It also summarizes the different potential mecha-
nisms involved in the link between osteoporosis and CVD.
KEY WORDS: osteoporosis, bone mineral density, cardiovascular disease,
atherosclerosis, vascular calcification.
Osteoporosis and cardiovascular disease
Cardiovascular disease (CVD) and osteoporosis are common
age-related conditions. Mounting biological and epidemiologi-
cal evidence supports a link between the two diseases. Low
bone mineral density (BMD) has been related to increased car-
diovascular mortality, cardiovascular morbidity, and subclinical
measures of atherosclerosis in cross-sectional as well as longi-
tudinal epidemiologic studies.
Biological link
Atherosclerotic calcification and bone mineralization share a
number of intriguing common features. It is now recognized
that calcification of the arterial tissue is not merely a passive
process of calcium phosphate precipitation or adsorption in
end-stage atherosclerosis, but instead is a highly organized
process that is regulated by mechanisms similar to those in-
volved in bone mineralization (1, 2).
The mineral observed in calcium deposits of atherosclerotic
plaques has a very similar chemical composition to hydroxyap-
atite crystals which form the inorganic bone matrix (3, 4). Calci-
fiable vesicles were isolated from human atherosclerotic aortas
(5), suggesting that these may be involved in mineral deposi-
tion, similar to “extracellular matrix vesicles” that are secreted
from chondrocytes and osteoblasts and are involved in initial
bone mineralization. Calcified plaques were also shown to ex-
press several bone matrix proteins such as type I collagen, gla
(gamma carboxyglutamate)-containing proteins such as osteo-
calcin (bone-gla protein) and matrix-gla protein, bone morpho-
genetic protein (BMP)-2 and -4, osteopontin, osteonectin, and
bone sialoprotein (3, 6-8). Osteogenic cells, called calcifying
vascular cells (CVCs), were identified in atherosclerotic
plaques. These are a subpopulation of vascular smooth muscle
cells (VSMC) that are capable of osteoblastic differentiation (3,
9). When stimulated by BMP-2 and BMP-4, these cells begin
expressing osteoblast genes including alkaline phosphatase,
collagen I, and osteocalcin which are needed for bone forma-
tion. Other cells involved in bone metabolism including osteo-
clast-like cells, chondrocyte-like cells, and hematopoietic bone
marrow cells were also seen in plaques (10).
Epidemiologic link
Bone mass and cardiovascular mortality 
Low BMD and bone loss appear to be risk factors for cardio-
vascular mortality in both women (11-14) and men (15, 16)
(Table I). The Study of Osteoporotic Fractures (SOF) showed
that an increase in BMD loss at the hip in the order of one
standard deviation (SD) was associated with a 1.3-fold in-
crease in CHD mortality among white women 65 years of age
and older. Similarly, calcaneal bone loss was related to in-
creased risk of death due to atherosclerosis [Relative Risk1
(RR = 1.2, 95% CI = 1.1-1.4) and CHD (RR = 1.3, 95% CI =
1.0-1.6)] (12). In the same cohort, lower broadband ultra-
sound attenuation (BUA) and calcaneal BMD were related to
higher cardiovascular death (11), and decreased BMD of the
proximal radius was related to increased risk of stroke mortal-
ity (RR = 1.91, 95% CI 1.25-2.92) (14). In a population of
Danish women, low bone mineral content in the forearm at
the menopause was associated with an increased cardiovas-
cular death later in life (RR = 2.3 per SD decrease in BMD,
95% CI 1.0-4.9). In the same study, a prevalent vertebral
compression fracture was independently associated with car-
diovascular death in late postmenopausal women (RR = 2.0,
95%CI 1.4-3.3) (13).
Similar results were observed in men. Results from the
NHANES I Epidemiologic Follow-up Study indicated that low
phalangeal BMD was a significant predictor of subsequent car-
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1 Relative Risk (RR) was used to refer to both Risk Ratios and Hazard Ratios.
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diovascular mortality among white men aged 45 to 74 years
(RR = 1.16, 95% CI 1.0-1.30). This association, however, was
not present in white women or blacks (15). In another prospec-
tive study, low bone density at the hip was found to be a signifi-
cant predictor of cardiovascular mortality in a cohort of British
men aged 65-76 years (16).
Contrary to the above studies, Mussolino et al. did not find a
significant association between BMD and stroke mortality in
white men, white women, or blacks in NHANES I (17).
Bone mass and cardiovascular morbidity
A number of studies have investigated the association between
BMD and cardiovascular morbidity (Table II). In a cross-sec-
tional analysis from the Health, Aging, and Body Composition
(ABC) Study, we observed that volumetric BMD (vBMD) mea-
sures of the spine were significantly and inversely associated
with prevalent CVD in men and women, and areal BMD (aB-
MD) of the trochanter was related to CVD in women (18). In a
longitudinal analysis from the same cohort, we found that vB-
MD measures of the spine were associated with incident CVD
in white men, but not in blacks. In women, aBMD measures of
the total hip, femoral neck, and trochanter exhibited significant
relationships with incident CVD in black women, but not in
whites. All of these associations were independent of age and
shared risk factors between osteoporosis and CVD, and were
not explained by inflammatory cytokines or oxidized LDL (Ta-
bles III and IV) (19). 
Other studies have reported significant associations between
osteoporosis and CVD in women. Results from the Multiple Out-
comes of Raloxifene Evaluation (MORE) trial indicated that os-
22 Clinical Cases in Mineral and Bone Metabolism 2008; 5(1): 19-34
G.N. Farhat et al.
Table III - Effect of controlling for IL-6, TNF-α, or oxLDL on the adjusted associations of aBMD measures with incident CVD in black women,
the Health, Aging, and Body Composition Study.
BMD N at risk Adjusted for risk factors* Adjusted for risk factors + IL-6, 
(events) Hazard Ratio (95% CI) TNF-α, or oxLDL**
Hazard Ratio (95% CI)
Total Hip aBMD
IL-6 502 (84) 1.39 (1.06-1.83)a 1.39 (1.06-1.82)a
TNF-α 486 (77) 1.32 (0.99-1.76)a 1.33 (1.00-1.77)a
oxLDL 524 (86) 1.32 (1.02-1.72)a 1.35 (1.03-1.77)a
Femoral Neck aBMD
IL-6 502 (84) 1.51 (1.14-1.99)b 1.49 (1.13-1.96)b
TNF-α 486 (77) 1.46 (1.09-1.96)a 1.48 (1.10-1.98)b
oxLDL 524 (86) 1.42 (1.09-1.86)b 1.44 (1.09-1.89)b
Trochanter aBMD
IL-6 502 (84) 1.36 (1.05-1.77)a 1.35 (1.05-1.74)a
TNF-α 486 (77) 1.32 (1.01-1.73)a 1.31 (1.01-1.72)a
oxLDL 524 (86) 1.32 (1.02-1.69)a 1.34 (1.03-1.72)a
* Models in women were adjusted for age, study site, physical activity, Health ABC physical performance score, BMI, cholesterol, systolic blood pressure, glu-
cose level, history of hypertension, and use of diabetes drugs, calcium supplements, and oral estrogen.
** oxLDL models did not include cholesterol level due to the high correlation between the two measures.
a p<0.05
b p≤0.01
Table IV - Effect of controlling for IL-6, TNF-α, or oxLDL on the adjusted associations of vBMD measures with incident in white men, the
Health, Aging, and Body Composition Study.
BMD N at risk Adjusted for risk factors* Adjusted for risk factors + IL-6,
(events) Hazard Ratio (95% CI) TNF-α, or oxLDL**
Hazard Ratio (95% CI)
Integral vBMD
IL-6 280 (62) 1.37 (1.01-1.86)a 1.38 (1.02-1.88)a
TNF-α 276 (63) 1.40 (1.04-1.89)a 1.40 (1.04-1.89)a
oxLDL 292 (66) 1.39 (1.04-1.87)a 1.41 (1.05-1.89)a
Cortical vBMD
IL-6 280 (62) 1.37 (1.02-1.85)a 1.38 (1.02-1.86)a
TNF-α 276 (63) 1.39 (1.03-1.86)a 1.38 (1.03-1.85)a
oxLDL 292 (66) 1.39 (1.04-1.85)a 1.41 (1.05-1.88)a
* Models in men were adjusted for: age, study site, education, physical activity, Health ABC physical performance score, BMI, HDL, LDL, systolic blood pres-
sure, glucose level, history of hypertension, and use of diabetes drugs.
** oxLDL models did not include LDL level due to the high correlation between the two measures.
a p<0.05
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teoporosis was a strong predictor of incident cardiovascular
events in postmenopausal women independent of age and other
traditional cardiovascular risk factors (adjusted RR = 3.9, 95%
CI 2.0-7.7) (20). Osteoporosis was also associated with angio-
graphically-determined coronary artery disease in a retrospec-
tive analysis of a population predominantly of women referred
for angiography and BMD assessment (21). A report from the 30
year follow-up of the Framingham study found that metacarpal
cortical area (MCA) predicts coronary heart disease in women
free from CVD at baseline, with a significant trend of decreasing
coronary heart disease risk with increasing MCA (RR for highest
vs. lowest MCA quartile = 0.73, 95% CI 0.53-1.00, p for trend =
0.03). No association, however, was observed in men in this
study (22). In SOF, low calcaneal bone mass was significantly
associated with stroke incidence (RR = 1.31 per SD, 95%CI
1.03-1.65) (23). In line with these findings, low femoral neck
BMD was associated with an increased odds of stroke in
women, but not in men, in a Norwegian population (24). 
Similar associations were also reported in men. A History of
myocardial infarction was associated with low BMD in a multi-
ethnic population of men in the Third National Health and Nutri-
tion Examination Survey (NHANES III) (25). Additionally, in a
study involving 18 men with asymmetrical symptomatic periph-
eral arterial disease, bone mineral content was shown to be
significantly lower in the affected compared to the unaffected
leg (26).
In contrast to the above studies, and consistent with their mor-
tality finding, Mussolino et al. found no relationship between
BMD and stroke incidence among white men, white women or
blacks in NHANES I (17).
Bone mass and subclinical atherosclerosis
An inverse relationship between bone mass and various mea-
sures of subclinical disease, especially in women, has been re-
ported by many studies (Table V). Cross-sectionally, vascular
calcification, in both the aorta (27-33) and the coronary arteries
(34, 35) was found to be negatively correlated with bone densi-
ty (28-33) and directly related to vertebral and hip fractures,
(28, 29) predominantly in white postmenopausal women. We
observed an inverse cross-sectional association between tra-
becular BMD of the spine and aortic calcification in a biracial
cohort of healthy middle-aged women from the Study of
Women’s Health Across the Nation (SWAN). This association
was not age-related, was independent of shared risk factors
between BMD and calcification, and was not influenced by
estradiol. Meanwhile, we noted no associations with coronary
artery calcification after adjusting for age (Fig. 1) (27).
The progression of aortic calcification was also linked to volumet-
ric trabecular BMD loss in white postmenopausal women, (28)
and to metacarpal bone loss in women in the Framingham study
and in a Dutch population-based longitudinal study (31, 36).
Ankle-arm index was positively correlated with BMD in an el-
derly population of Chinese men and women (37) and in Euro-
pean postmenopausal women (38). In SOF, women with the
highest decline in AAI were shown to have the largest magni-
tude of bone loss (39).
Femoral artery intima-media thickness was negatively related to
calcaneal osteo-sono assessment index (OSI) in a population of
Japanese men and women (40). In another small group of post-
menopausal Japanese women, higher carotid plaque score was
significantly associated with lower total BMD (41). Low BMD was
also related to echogenic calcified carotid artery plaques in a
large population of Norwegian men and postmenopausal women
(42). And in a small case-control study in an Italian population of
men and postmenopausal women, patients with atherosclerotic
involvement of the carotid and/or femoral artery had low bone
mass, and significantly lower osteocalcin and bone-specific alka-
line phosphatase than controls (43). In another Italian population
of postmenopausal women, the prevalence of carotid atheroscle-
rosis was higher among women with low BMD and osteocalcin
levels above the median (44).
Additionally, pulse wave velocity (PWV), a marker of early
stage atherosclerosis, was inversely associated with calcaneal
quantitative OSI in a large Japanese population with a median
age of 50 years. This association was stronger in women than
men and in pre-menopausal than postmenopausal women
(45). A recent report on forearm endothelial function and spine
BMD in early postmenopausal Japanese women indicated that
osteoporotic women had a lower maximal forearm blood flow
response to reactive hyperemia than those with normal BMD or
osteopenia (46).
Other studies have failed to observe an association between
osteoporosis and subclinical measures of atherosclerosis. In
the Framingham Study, vascular calcification was not found to
increase long-term hip fracture risk (47). In SOF, no significant
association was observed between aortic calcification and
bone density at the hip, spine, or calcaneus after adjusting for
age; only a weak association with radial BMD was noted (48).
These findings were consistent with others reported by Frye et.
al. among women in Rochester, Minnesota (49), by Aoyagi et.
al. in Japanese-American women (50), and by Anderson et al.
in a population of British men and women (51). 
Limitations of the existing epidemiologic literature 
Most of the previous reports relied on white postmenopausal
women and blacks have been excluded from analyses due to
their reduced risk for osteoporosis and fractures (11-14, 20-24,
28-30, 32, 34, 36, 39, 44, 48, 49). Given the well-known racial
differences in the burdens of CVD and osteoporosis, an investi-
gation into the association between the two diseases in sepa-
rate ethnic groups is warranted.  
Additionally, a number of studies did not exclude people with
baseline CVD from analyses (11, 12, 14-17, 20, 23, 24, 28, 30,
31, 36-39, 42, 44, 48, 50). Therefore, those associations might
have been confounded by factors such as reduced physical ac-
tivity ensuing from CVD, which in itself contributes to lower BMD.
In a large number of studies, bone mass was determined using
radiographic techniques, single-photon or single X-ray absorp-
tiometry, or dual-photon absorptiometry (13-15, 17, 22, 23, 31,
33, 36, 42, 44, 45, 50, 51). Some studies have employed DXA
in bone determination (11, 12, 16, 20, 21, 24-26, 29, 30, 34,
35, 37-41, 43, 46, 48); however, this technique is limited by its
2-dimensional areal assessment of BMD which does not adjust
for bone size. This is especially important in studies of different
ethnic and gender groups since there are well-established dif-
ferences in bone size by race and gender (52, 53). DXA is also
affected by the presence of extra-osseous calcium such as
aortic calcification and degenerative osteoarthritic changes,
which get incorporated in the region of interest and lead to a
falsely increased bone density at the spine (32). This is an im-
portant drawback, particularly in the elderly who have an in-
creased prevalence of such degenerative conditions (54).
Quantitative computed tomography (QCT) allows for a three-di-
mensional volumetric determination of bone density, an adjust-
ment for bone size, and an assessment of purely trabecular
bone. Only a few studies have utilized QCT for BMD assess-
ment (18, 19, 27, 28, 32).
Another limitation for the existing epidemiologic studies is that
some reports did not sufficiently control for important covari-
ates including physical activity, lipids, blood pressure, and the
use of medications such as statins (11, 12, 14, 15, 17, 20, 23,
24, 26, 28, 31-39, 41, 43, 46, 48, 50, 51).
Clinical Cases in Mineral and Bone Metabolism 2008; 5(1): 19-34 23
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Potential mechanisms for the link between osteoporosis
and cardiovascular disease
The nature of the putative link between osteoporosis and car-
diovascular disease remains unclear. Traditionally, these two
conditions were considered unrelated and their progression
was attributed to independent age-related processes (48-50).
However, recent evidence from many studies points to a link
between osteoporosis and CVD that cannot be explained by
age alone. While this evidence has been consistent in older
populations, further support for the role of factors other than
age is derived from observations in younger populations. For
instance, osteoporotic fractures and cardiovascular outcomes
have been shown to coexist in young women with systemic lu-
pus erythematosus (SLE), an autoimmune systemic inflamma-
tory disease that predominantly affects young premenopausal
women. The increased risk for both conditions in this young
group suggests that factors beyond age are at play in the
pathogenesis of osteoporosis and CVD (35). Several hypothe-
ses have been proposed to explain the link between the two
conditions. 
1. Shared risk factors
One hypothesis puts forth that the coexistence of osteoporosis
and CVD is due to their shared etiological factors (such as
smoking, physical activity, alcohol intake, menopause, hyper-
tension, etc), which may simultaneously promote or inhibit ath-
erosclerosis and bone demineralization, and could partly ex-
plain the association between the two diseases (16, 30, 55,
56). However, in many epidemiologic studies, the association
between osteoporosis and CVD remained even after the ad-
justment of some of these risk factors. 
2. Common pathophysiological mechanisms
Common pathophysiological mechanisms involving inflamma-
tory cytokines, (43) endogenous sex hormones (16, 45), oxi-
dized lipids (57), vitamin K deficiency (58), and vitamin D (59)
were implicated in the progression of the two conditions.
Inflammatory markers and cytokines
Inflammation is known to play a central role in all stages of
atherogenesis from fatty streak formation to plaque rupture (60),
and there is evidence for its involvement in bone loss. Animal
models suggest that osteopenia can be induced in rats by trig-
gering a generalized inflammation through the subcutaneous ad-
ministration of nonspecific irritants (such as magnesium silicate
and cellulose) (61). This induced osteopenia was mainly due to
inhibition of bone formation (62). Chronic inflammatory diseases
such as rheumatoid arthritis, lupus, and Crohn’s disease are as-
sociated with a significant risk for secondary osteoporosis and
fractures. The pathogenesis of osteoporosis in these settings is
attributed to systemic inflammatory processes among other fac-
tors such as glucocorticoid therapy (63). 
Inflammation is a complex process that is mediated by many
cytokines including IL-1, TNF-α, and IL-6. Aging is associated
with increased levels of circulating inflammatory cytokines such
as IL-6 and TNF-α (64). IL-6 was shown to stimulate osteo-
clasts, thereby increasing the rates of bone remodeling and
bone loss (65). This cytokine was also observed to act as a
marker of subclinical CVD in elderly people (66) and to predict
CVD mortality in relatively healthy people aged 65 years and
older (67). TNF-α was also shown to stimulate bone resorption
and inhibit bone formation (68). Results from the Health ABC
study indicated that TNF-α and IL-6 were significantly associat-
ed with prevalent clinical and subclinical disease (69), as well
as incident cardiovascular events (70). In the same cohort, ele-
vated levels of these inflammatory cytokines were related to in-
creased risk of fracture (71).
Other cytokines may be involved. The OPG/RANK/RANKL tri-
ad, a novel signaling pathway recognized as a key regulator of
bone resorption, was also shown to play a role in vascular cal-
cification. OPG deficient mice were found to develop early-on-
set osteoporosis and calcification of the aorta and renal arter-
ies (72). In another animal study, OPG was shown to be a po-
28 Clinical Cases in Mineral and Bone Metabolism 2008; 5(1): 19-34
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Figure 1 - Adjusted odds ratios for moderate and high aortic and coronary calcification* (relative to no calcification) per 1SD decrease in vBMD** 
* Aortic calcification model: adjusted for age, race, study site, menopause status, educational level, smoking status, physical activity score, weight, height, dias-
tolic blood pressure, LDL, and triglyceride level. Coronary artery calcification model: adjusted for age, race, study site, menopause status, alcohol drinking,
physical activity score, weight, height, diastolic blood pressure, LDL, and triglyceride level.
** vBMD SD= 37.2 mg/cc 
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tent inhibitor of warfarin- and vitamin D-induced arterial calcifi-
cation at doses known to inhibit bone resorption (73). In epi-
demiologic studies, low OPG levels were related to higher
prevalence of osteoporosis and vertebral fractures (74). In-
creased osteoprotegerin levels were also associated with high-
er prevalence of CAD, suggesting that elevated OPG may re-
flect a compensatory mechanism to prevent further vascular
damage (75).
Endogenous sex hormones
Estrogen deficiency has been identified as the major determi-
nant of age-related bone loss in women and men (76, 77).
Despite recent evidence from randomized, placebo-controlled
trials on the adverse effects or lack of effects of post-
menopausal hormone therapy on CVD outcomes (78, 79), en-
dogenous estrogen may have protective effects on the car-
diovascular system in women. Estradiol prevents endothelial
dysfunction by increasing the proliferation of endothelial cells,
regulating the production of endothelium-derived factors such
as nitric oxide, and decreasing the expression of leukocyte
adhesion molecules. It inhibits the proliferation and migration
of smooth muscle cells. It is also known to improve the lipid
profile (80). Estrogen receptor alpha (ESR1) was shown to
have an effect on CVD susceptibility in both women and men
(81). Estrogen may be involved in the pathogenesis of athero-
genesis and bone loss, either directly (80, 82), or through
modulation of other factors including cytokines (83) and oxi-
dized lipids (80). The direct effect of estrogen is manifested
by the expression of estrogen receptors on osteoblasts, os-
teoclasts (84), and vascular endothelial and smooth muscle
cells (80).
Androgens also seem to have an effect on bone and vascular
health. A positive correlation between testosterone levels and
bone density has been observed in men and women (85, 86).
Androgens were also related to cardiovascular risk factors in
men (87) and perimenopausal women (88) and to aortic ather-
osclerosis in men (89).
Lipid metabolism and oxidized lipids
Oxidized lipids have been suggested as a potential mecha-
nism for the paradoxical occurrence of bone loss with vascu-
lar calcification. The role of oxidized lipids in atherogenesis is
well established (60, 90). In vitro, Parhami et al. have ob-
served that lipid oxidation products including, minimally oxi-
dized LDL, ox-PAPC (oxidized 1-palmitoyl-2-arachidonyl-sn-
glycero-3-phosphocholine), and the isoprostane iso-PGE2,
have opposite effects on the differentiation of calcifying vas-
cular cells (CVCs) and bone cells. Oxidized lipids were found
to stimulate osteoblast differentiation in CVCs as manifested
by their induction of alkaline-phosphatase, a marker of os-
teoblastic differentiation (91), and their promotion of the for-
mation of extensive areas of calcification in CVCs. In con-
trast, the same lipids were observed to inhibit osteoblast dif-
ferentiation in bone by depressing the induction of alkaline
phosphatase activity and reducing mineralization in pre-
osteoblastic bone cells. This lead to the suggestion that the
accumulation of oxidized lipids in the subendothelial space of
arteries promotes arterial calcification, and its accumulation in
the subendothelial space of osteons may inhibit bone miner-
alization (57).
A growing body of evidence suggests a negative effect of an
atherogenic lipid profile on bone formation. In a cohort of post-
menopausal women, plasma levels of low density lipoprotein
cholesterol (LDL-C) and high density lipoprotein cholesterol
(HDL-C) were negatively and positively related to BMD, re-
spectively (92). In animal studies, an atherogenic high-fat diet
was found to reduce bone formation in mice (93). The adverse
effects of dyslipidemia are mediated by the resultant increase
in lipid oxidation products. Increased levels of circulating lipids
result in the diffusion of lipoproteins across the vascular en-
dothelium and their accumulation inside the arterial wall and in
highly vascular tissues such as the bone microenvironment.
Once outside the plasma, these lipid products are subjected to
oxidative modification, thus becoming biologically active mole-
cules capable of affecting a variety of cellular processes that
ultimately result in atherogenesis and bone loss (93).
In line with the lipid hypothesis, a potent class of lipid lower-
ing drugs, the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitors (commonly referred to as statins),
is suggested to have an effect on bone health (94, 95).
Statins inhibit HMG-CoA reductase, the enzyme that cat-
alyzes the rate-determining step of cholesterol biosynthesis,
the reductive de-acylation of HMG-CoA to mevalonate. In
large clinical trials, statins have demonstrated the ability to
markedly reduce total cholesterol, LDL-C, and triglycerides,
to increases HDL-C, and to reduce the incidence of cardio-
vascular events and mortality (96, 97). Recent evidence sug-
gests that statin use is related to higher BMD (98) and re-
duced fracture risk (96, 97). In vitro and in animal studies,
statins were found to stimulate bone formation and enhance
osteoblast differentiation, by increasing the expression and
production of BMP-2 by human osteoblasts (99). Like other
members of the BMP family, BMP-2, is known to enhance os-
teoblast differentiation (100).
Another class of drugs, bisphosphonates, which inhibit bone
resorption and are widely used for the treatment of osteo-
porosis, may have cardiovascular effects. Like statins, nitro-
gen-containing bisphosphonates also act on the cholesterol
biosynthesis pathway, however; they target enzymes more
distal in the mevalonic acid pathway than HMG Co-A reduc-
tase (95). These drugs were found to have unexpected ef-
fects on lipids in postmenopausal women with osteoporosis.
Chronic intravenous therapy with neridronate was shown to
decrease LDL-C and apolipoprotein B and to increase HDL-C
(101).
Vitamin K deficiency
Vitamin K deficiency was suggested as a common denomina-
tor for atherosclerotic calcification and low bone mass (58).
Low vitamin K intake was related to low bone density (102)
and increased risk of osteoporotic fracture (103). Intake of
menaquinone (vitamin K-2) was inversely associated with all-
cause mortality, CHD mortality, and severe atherosclerosis in
the Rotterdam study (104). Impaired vitamin K status was al-
so linked to increased atherosclerotic calcification in post-
menopausal women (105). Additionally, Jie and colleagues
have observed an inverse association between markers of vi-
tamin K status and bone mass in atherosclerotic women;
whereas, no such association was found in the non-athero-
sclerotic group. It is speculated that the effect of vitamin K on
bone demineralization and vascular calcification is mediated
by a vitamin K-dependent class of proteins, gla-containing
proteins, which include matrix gla protein (MGP) and osteo-
calcin. Gla-containing proteins are thought to be involved in
calcium metabolism and in the process of calcification in
bone and vascular tissues due to the calcium-binding proper-
ties of their gla residues (58). These residues are acquired
post-translationally by the action of vitamin K that functions
as a coenzyme for glutamate carboxylase, an enzyme that
mediates the conversion of glutamate to γ-carboxyglutamate
(Gla). The exact physiological role of these proteins is still not
clear. However, it is hypothesized that the undercarboxylation
of MGP, a mineralization inhibitor, is a risk factor for vascular
Clinical Cases in Mineral and Bone Metabolism 2008; 5(1): 19-34 29
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calcification, and that the undercarboxylation of osteocalcin, a
marker of osteoblastic activity, disrupts the normal bone re-
modeling process mediated by osteocalcin and results in
bone loss (58).
Vitamin D metabolism
Imbalances in the calciferol endocrine system may also be in-
volved. The role of vitamin D deficiency in the pathogenesis of
osteoporosis is well-established (106). Reduced levels of vita-
min D were also associated with increased incident cardiovas-
cular disease in the Framingham Offspring Study (107).
On the other hand, excess vitamin D was shown to induce ath-
erosclerosis and osteoporosis in humans and laboratory ani-
mals, and the use of vitamin D as a food supplement in some
countries coincided with an increase in the incidence of both
conditions (59). Vitamin D receptor (VDR) polymorphisms are
also suggested to simultaneously contribute to the risk of both
osteoporosis and CVD (108).
Hyperparathyroidism
Parathyroid hormone (PTH) is one of the main regulators of
calcium homeostasis. It stimulates the release of calcium and
phosphate from bones. Aging is associated with increased lev-
els of PTH as a result of vitamin D deficiency and decreased
calcium intake and absorption. Elevated PTH levels contribute
to the age-related bone loss and bone fragility (109, 110). Sec-
ondary hyperparathyroidism was also linked to increased risk
for fractures, cardiovascular outcomes, and vascular calcifica-
tion in end-stage renal disease (110, 111).
Homocysteine
Homocysteine is a variant of the amino acid cysteine and is
formed during the metabolism of methionine. Its degradation
requires folic acid and vitamin B12 as cofactors. Elevated lev-
els of homocysteine could result from genetic or nutritional fac-
tors and may lead to osteoporosis and atherosclerosis. Homo-
cystinuria, a genetic disorder of cystathionine β-synthase defi-
ciency, results in early onset osteoporosis and cardiovascular
events. There is considerable evidence that elevated plasma
homocysteine levels are associated with an increased risk of
vascular disease. Homocysteine was reported to enhance the
proliferation of vascular smooth muscle cells, inhibit the regen-
eration of endothelial cells, and increase lipid oxidation (112).
High homocysteine levels were also associated with osteo-
porotic fractures (113) and reduced BMD (114). Homocysteine
was observed to impair bone mineralization (115) and inhibit
collagen cross-linking (116).
Other factors
Other factors implicated in the pathogenesis of atherosclerosis
and bone loss include nitric oxide, endothelin-1, angiotensin
converting enzyme activity, ascorbic acid, potassium, hyper-
phosphatemia, oxidative stress, and the preferential differentia-
tion of bone marrow stromal cells into smooth muscle cells
over osteoblasts. 
3. Common genetic factors
The osteoprotegerin, matrix-gla protein, and apolipoprotein E
(ApoE) genes have been invoked in both atherogenesis and
bone loss. Mice lacking the osteoprotegerin gene were found to
develop early-onset osteoporosis and calcification of the aorta
and renal arteries (72). Similarly, mice lacking the gene for matrix
gla protein exhibited vascular calcification as well as osteopenia
and fractures (117). ApoE genotype was associated with athero-
sclerosis in the Framingham Study and in patients with end stage
renal disease (118, 119). The ApoE4 gene was also associated
with reduced BMD and increased fracture risk (120, 121).
4. Causal association
Other hypotheses point to a causal association between the
two conditions whereby one of them may lead to the other. 
The reduced blood flow hypothesis assumes that atherosclero-
sis, by reducing blood flow to the lower extremities, could affect
intraosseous blood circulation. This in turn alters bone metabo-
lism in the hip and results in osteoporosis. This hypothesis is
supported by a study which showed that in cases of asymmet-
rical peripheral arterial disease, hip bone mineral content was
lower in the affected leg compared to the unaffected one (26,
122). Consistent with this finding, low ankle-arm index was as-
sociated with low BMD at the femoral neck, but not at the spine
in the Rotterdam Study (38). Additionally, BMD at the hip, but
not at the spine or radius, showed an inverse relation with aor-
tic calcification - a condition thought to affect blood flow to the
distal regions or reflect atherosclerosis in arteries directly re-
sponsible for blood supply to the hip (30). In line with this theo-
ry, one histological study of 100 cadavers, reported the exis-
tence of atherosclerotic changes in intraosseous arteries and
arterioles of the femur (123).
Physical activity was also suggested to lie on the causal path-
way between atherosclerosis and bone loss. CVD might limit
physical activity and accordingly contribute to bone loss (23).
It is also hypothesized that as a result of the progressive bone
loss leading to osteoporosis, calcium and phosphate salts get
redirected from the bone matrix to the arterial wall (33, 34, 48,
124, 125).
Future research
Additional longitudinal studies are needed to confirm the asso-
ciation between osteoporosis and CVD. Furthermore, racial dif-
ferences in this association deserve further investigation. 
Examination of the relation between bone loss and the pro-
gression of vascular calcification is certainly warranted. A sub-
clinical assessment of CVD may allow for osteoporosis risk
stratification and the early identification of subjects at high risk
for developing the condition, and vice versa. 
Another key avenue for future research is the elucidation of the
common mechanisms underlying the link between osteoporo-
sis and CVD. An understanding of these mechanisms will set
the stage for the potential use of common preventive and ther-
apeutic interventions targeted at both conditions. 
Conclusion
CVD and osteoporosis are major causes of morbidity, mortality,
and disability. Both diseases increase with aging. Traditionally,
these two conditions were considered unrelated and their coex-
istence was attributed to independent age-related processes.
Recently, an increasing body of biological and epidemiological
evidence has provided support for a link between the two con-
ditions beyond age and shared risk factors. It is suggested that
common molecular, cellular, and biochemical processes are
implicated in their pathogenesis. 
New paradigms for treatment and prevention of both CVD and
osteoporosis may emerge from investigating the link between
the two conditions and elucidating the mechanisms involved in
30 Clinical Cases in Mineral and Bone Metabolism 2008; 5(1): 19-34
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their progression. An understanding of the biological linkages
may set the stage for dual-purpose preventive and therapeutic
interventions aimed at reducing bone loss and the progression
of atherosclerosis.
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